A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort

European Urology

Volumn 69, Issue 3, 2016, Pages 505-511

  Braun, Katharina ^a   Sjoberg, Daniel D ^b   Vickers, Andrew J ^b   Lilja, Hans ^b,c,d   Bjartell, Anders S ^d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Biopsy; Four kallikrein panel; Prostate cancer; Prostate specific antigen

Indexed keywords

BETA MICROSEMINOPROTEIN; FREE PROSTATE SPECIFIC ANTIGEN; INTACT PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 2; PROSTATE SPECIFIC ANTIGEN; TOTAL PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; BETA-MICROSEMINOPROTEIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; KLK2 PROTEIN, HUMAN; PROSTATIC SECRETORY PROTEIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HIGH GRADE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; STATISTICAL MODEL; AREA UNDER THE CURVE; BIOPSY; BLOOD; CANCER GRADING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SWEDEN; UNNECESSARY PROCEDURE; VALIDATION STUDY;

AGED; AREA UNDER CURVE; BIOPSY; DIGITAL RECTAL EXAMINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SWEDEN; UNNECESSARY PROCEDURES;

EID: 84929095505     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.04.028     Document Type: Article

References (30)

1. A.J. Vickers, A.M. Cronin, T. Bjork, and et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
2. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
3. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
4. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
5. H. Lilja, D. Ulmert, and A.J. Vickers Prostate-specific antigen and prostate cancer: prediction, detection and monitoring Nat Rev Cancer 8 2008 268 278
6. A. Benchikh, C. Savage, A. Cronin, and et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France BMC Cancer 10 2010 635
7. A. Gupta, M.J. Roobol, C.J. Savage, and et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands Br J Cancer 103 2010 708 714
8. V. Vaisanen, M.T. Peltola, H. Lilja, and et al. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments Anal Chem 78 2006 7809 7815
9. A. Vickers, A. Cronin, M. Roobol, and et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
10. A.J. Vickers, A.M. Cronin, G. Aus, and et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden BMC Med 6 2008 19
11. A.J. Vickers, A.M. Cronin, M.J. Roobol, and et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam Clin Cancer Res 16 2010 3232 3239
12. C.A. Haiman, D.O. Stram, A.J. Vickers, and et al. Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations J Natl Cancer Inst 105 2013 237 243
13. R.A. Eeles, Z. Kote-Jarai, G.G. Giles, and et al. Multiple newly identified loci associated with prostate cancer susceptibility Nat Genet 40 2008 316 321
14. G. Thomas, K.B. Jacobs, M. Yeager, and et al. Multiple loci identified in a genome-wide association study of prostate cancer Nat Genet 40 2008 310 315
15. R.K. Nam, J.R. Reeves, A. Toi, and et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis J Urol 175 2006 1291 1297
16. J.R. Reeves, H. Dulude, C. Panchal, and et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy Clin Cancer Res 12 2006 6018 6022
17. D.F. Gleason Histologic grading of prostate cancer: a perspective Hum Pathol 23 1992 273 279
18. K. Mitrunen, K. Pettersson, T. Piironen, and et al. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum Clin Chem 41 1995 1115 1120
19. D. Ulmert, C. Becker, J.A. Nilsson, and et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C Clin Chem 52 2006 235 239
20. P. Nurmikko, K. Pettersson, T. Piironen, and et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146 Clin Chem 47 2001 1415 1423
21. T. Piironen, J. Lovgren, M. Karp, and et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum Clin Chem 42 1996 1034 1041
22. P.A. Abrahamsson, C. Andersson, T. Bjork, and et al. Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women Clin Chem 35 1989 1497 1503
23. C. Valtonen-Andre, C. Savblom, P. Fernlund, and et al. Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males J Androl 29 2008 330 337
24. P. Nurmikko, V. Vaisanen, T. Piironen, and et al. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA Clin Chem 46 2000 1610 1618
25. R.J. Bryant, D.D. Sjoberg, A.J. Vickers, and et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study J Natl Cancer Inst 107 2015 djv095
26. J.A. Lane, J.L. Donovan, M. Davis, and et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial Lancet Oncol 15 2014 1109 1118
27. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
28. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
29. D.J. Parekh, S. Punnen, D.D. Sjoberg, and et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer Eur Urol 68 2015 464 570
30. D.J. Kaplan, S.A. Boorjian, K. Ruth, and et al. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population BJU Int 105 2010 334 337